Short CV/Education and training

  • 2010
    Strategic Professorship in Cell and Tumor Biology from Karolinska Institutet

  • 2003
    Senior Researcher Position in Clinical Molecular Biology from Swedish Research Council, MTC, KI

  • 2002
    Associate Professor (Docent), Karolinska Institutet

  • 2001
    Group leader, Dept. of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet

  • 1997
    4-year Assistant Professor position from Karolinska FoN

  • 1995 – 1996
    Swedish Cancer Society Guest Researcher Fellowship

  • 1993 – 1994
    The Wenner-Gren Foundation Postdoc Fellowship

  • 1993
    KI Postdoc Fellowship (declined)

  • 1992 – 1997
    Postdoctoral Fellow, Department of Tumor Biology and Microbiology and Tumor Biology Center (MTC), Karolinska Institutet, Stockholm, Sweden (laboratory of Klas G. Wiman)

  • 1991
    PhD, Institute of Genetics, Moscow, Russia.

Selected publications

  • Grinkevich V, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, and Selivanova G. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. (2009) Cancer Cell, 15(5):441-53

  • Enge M, Bao W, Hedström E, Jackson SP, Moumen A, and Selivanova G. MDM2-dependent downregulation of p21 and hnRNPK provides a switch between apoptosis and growth arrest induced by pharmacologically reactivated p53 (2009). Cancer Cell, 3;15(3):171-83.

  • Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G.G.C., Masucci, M., Pramanik, A., and Selivanova, G. (2004). Small molecule RITA binds to p53, blocks p53/HDM-2 interaction and activates p53 function in tumors. Nat Med., 10 (12), 3121-1328.

  • Bykov, V., Issaeva, N., Shilov, A., Hultcrantz M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K.G., and Selivanova, G. (2002) Restoration of the tumor suppressor function of mutant p53 by a small molecule, Nat. Med., 8 (3), 282-288.

  • Selivanova, G., Iotsova, V., Okan I., Fritsche M., Ström, M., Grafsröm, R., and Wiman, K. G. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3, 632-638.

  • Li H, Zhang Y, Ströse A, Tedesco D, Gurova K, Selivanova G. Integrated high- throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ. 2014, Sep;21(9):1493-502, Epub 2014 Jun 27.

    7. Shi Y., Nikulenkov F., Zawacka-Pankau J., Li H., Gabdoulline R., Xu J., Eriksson S., Hedström E., Issaeva N., Kel A., Arnér E., and Selivanova G. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Diff, 2014, 21:4; 612-23 This paper has been awarded a prize of 20 000 Euro by German Cancer Aid (Stiftung Für Die Erforschung ung Bekämpfung der Krebsklarnkheiten)

  • Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 2013 Sep 15;19(18):5092-103. doi: 10.1158/1078-0432.CCR-12-2211. Epub 2013 Jul 17.

  • Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, Taipale J, Selivanova G. Insights into p53 transcriptional function via genome-wide chtromatin occupancy and gene expression analysis. (2012) Cell Death Differ. Dec;19(12):1992-2002. This article has been recommended as being of special significance in its field by the F1000 Faculty:

  • Zawacka-Pankau J, Grinkevich VV, Hunten S, Nikulenkov F, Gluch A, Li H, Enge M, Kel A, Selivanova G. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem. 2011 Dec 2;286(48):41600-15.

Complete list of publications

Selected projects

  • Reactivation of mutant p53 by a synthetic peptide

  • Restoration of the tumor suppression function of mutant by a small molecule: from lab bench to clinic Exploring p53 regulation and p53 transcription function: friends and foes

Membership in scientific bodies/juries

Member of the Grant Evaluation Boards of

  • Swedish Research Council, Medicine, 2006 – 2010

  • Swedish Cancer Society, since 2013

  • Norwegian Research Council, PANELFYS-2, 2011 – 2014

  • French National Cancer Institute, 2009 – 2015

  • Karolinska Institute, 2009 – 2011

  • Robert Lundeberg’s Foundation, 2008

  • Alex and Eva Wallström foundation, 2012 – 2016

  • Postgraduate education at KI, 2010 – 2012

  • Ragnar Söderberg Foundation, 2015 – 2016

  • Norwegian Cancer Society, since 2017

Reviews of grant applications for

  • Cancer Research UK, Medical Research Council (UK)

  • Italian Ministry for Education

  • University and Research

  • Italian National Cancer Institute “Regina Elena”

  • Italian Foundation for Cancer Research

  • Dutch Cancer Society

  • Association for International Cancer Research (AICR)

  • Israeli Ministry of Science and United States/Israel Binational Science Foundation

  • The Fund for Scientific Research-FNRS (Belgium)


You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here


  1. Read what our members say about AcademiaNet.

Follow us

No more excuses!

  1. Please download the brochure "No more excuses" and read more about female experts in Europe, and about AcademiaNet.

Similar profiles

  1. Prof. Dr. Wiebke Arlt

    Health, Endocrinology

  2. Prof. Avan Aihie Sayer

    Health, Academic Medicine

  3. Prof. Anne Angelillo-Scherrer

    Biological and related sciences, Health, Internal medicine, Hematology - hemostasis, Clinical laboratory sciences - hematology

  4. Prof. Dr. Heike Allgayer

    Biological and related sciences, Health

Academia Net